NMPA Tavneos coverage for business development, investment, and market access teams
Kissei Pharmaceutical has urged doctors to halt the use of Tavneos after 20 deaths were reported in clinical trials. This development raises significant concerns for stakeholders.
We use cookies to enhance your experience, analyze traffic, and for marketing. By continuing to use our site, you consent to our use of cookies. Privacy Policy
